Here are the 10-K annual reports from Bone Biologics Corp (BBLG) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-K covers the audited annual report, with the full financial statements, so if you follow BBLG and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full BBLG filings page.
Bone Biologics Corporation files its annual report outlining a clinical-stage spine fusion business built around its NELL-1/DBM bone regeneration platform licensed from UCLA. The company is running a first-in-man pilot lumbar fusion study in Australia and plans a future U.S. pivotal trial.
Bone Biologics reports a net loss of approximately $3.1 million for the year ended December 31, 2025 and an accumulated deficit of about $88.1 million, with its auditor expressing substantial doubt about its ability to continue as a going concern. Available cash is expected to fund operations into the fourth quarter of 2026, and the company warns it must raise additional capital, navigate extensive FDA and international regulation, and meet significant royalty and milestone obligations under its exclusive UCLA license while competing against much larger orthopedic players.